An example is the drug ALRN-6924 (Stapled Peptide), currently in clinical trials, which binds to MDM2/MDMX and prevents their interaction with p53, thereby activating the p53 pathway in cancer cells [141,142,143]. This evidence concerns the gene TP53 and cancer.